Nephros Inc - NEPH STOCK NEWS

Nephros, Inc. (Nasdaq: NEPH) anticipates revenues of approximately $2.3 million for Q4 2020, reflecting a 9% sequential growth from Q3, but a 27% decline year-over-year. Full-year revenue is expected to be around $8.5 million, down 17% from 2019. CEO Andy Astor noted that COVID-19 significantly impacted 2020 revenues, particularly in acquiring new customers and sales in hospitality sectors. However, the company expressed optimism for recovery and growth as vaccine distribution expands. Nephros ended the year with approximately $8.3 million in cash.

Nephros Inc. (Nasdaq: NEPH) has announced the completion of the second-generation HDF Assist Module (HDF2) and plans to file a Special 510(k) with the FDA in early 2021. Despite delays, they expect to launch HDF2 post-COVID-19 vaccination rollout. Nephros also received a patent for HDF2 technology, valid until 2038, enhancing its market positioning. Additionally, they expanded the EndoPur and S100 filter capabilities for heat disinfection, potentially doubling their market reach. These advancements aim to improve water purification in dialysis and medical facilities.

Nephros (NASDAQ: NEPH) has completed its second-generation HDF Assist Module (HDF2) technology and will file a Special 510(k) with the FDA in early 2021, delaying its original timeline. The company has also been granted a patent for the HDF2 design, which will protect its technology until 2038. Additionally, Nephros has enhanced the EndoPur and S100 product lines to withstand heat disinfection, potentially doubling their market reach. Nephros anticipates that commercial launches for the HDF2 module will occur after COVID-19 vaccinations are largely completed.

Nephros, a company listed on Nasdaq under the symbol NEPH, announced its participation in upcoming investor conferences in November 2020. The Virtual Fall Investor Summit is scheduled for November 16, 2020, at 9:30 AM ET, with a webcast available. The Craig-Hallum Capital Group's 11th Annual Alpha Select Conference follows on November 17, and the Sidoti Virtual Microcap Conference will take place on November 19, at 11:30 AM ET. Nephros specializes in water purification products and pathogen detection systems for medical and commercial markets.

Nephros, Inc. (Nasdaq:NEPH) has appointed Dan D'Agostino as its Chief Financial Officer, effective November 6, 2020. The company reported a 34% quarter-over-quarter increase in net revenue for Q3 2020, totaling $2.1 million, although this reflects a 31% decline year-over-year. The net loss widened to $1.0 million from $0.7 million in the previous year. Despite the challenges of the COVID-19 pandemic, Nephros maintains strong recurring revenues and customer retention. The company aims to expand its filtration business and enhance its pathogen detection products.

Nephros, a company focused on water purification and pathogen detection, announced it will release its third quarter 2020 financial results on November 5, 2020, after market close. The company will also host a conference call at 4:30 PM ET on the same day to discuss financial results and provide a business overview. Nephros targets medical and commercial markets with ultrafilters and pathogen detection systems, crucial for infection control in healthcare settings.

Nephros, Inc. (Nasdaq: NEPH) announced a registered direct offering of 833,333 shares at $6.00 each, estimated to gross $5.0 million. The offering's expected closure is on or around October 20, 2020, subject to customary conditions. Proceeds will be allocated for working capital and general corporate purposes. The shares are offered under an effective shelf registration statement filed with the SEC. B. Riley Securities is the lead financial advisor for this offering.

Nephros, Inc. (Nasdaq: NEPH) has announced the launch of DialyPath, an innovative assay that rapidly estimates endotoxin levels in dialysis water samples within two hours. This on-site testing solution is designed to enhance patient safety by identifying waterborne bacterial contamination, correlating highly with the industry-standard LAL assay. With a lower limit of quantification at 0.001 EU/ml, DialyPath significantly improves testing efficiency compared to traditional methods that take 2-3 days. The product does not rely on endangered horseshoe crab blood cells, making it a more sustainable choice.

Nephros, Inc. (Nasdaq: NEPH), a company specializing in high-performance water purification and pathogen detection systems, will present at the MicroCap Rodeo Best Ideas Bowl from October 13-16, 2020. Scheduled for October 13 at 11:30 AM ET, the presentation will be webcast live for attendees. The conference features 25 select companies, recommended as top ideas by institutional investors, aiming to showcase potential investment opportunities. Nephros is known for its ultrafilters used in various medical and commercial applications, ensuring water safety and quality.